{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:19:14Z","timestamp":1792819154509,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,3,8]],"date-time":"2014-03-08T00:00:00Z","timestamp":1394236800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00280-014-2424-x","type":"journal-article","created":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T09:58:08Z","timestamp":1394186288000},"page":"931-941","source":"Crossref","is-referenced-by-count":41,"title":["Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors"],"prefix":"10.1007","volume":"73","author":[{"given":"Kelly K.","family":"Curtis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald W.","family":"Northfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry M.","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Whisnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Leuschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Alila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh K.","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,8]]},"reference":[{"key":"2424_CR1","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0024-3205(03)00113-9","volume":"72","author":"AV Schally","year":"2003","unstructured":"Schally AV, Nagy A (2003) New approaches to treatment of various cancers based on cytotoxic analogs of LH-RH, somatostatin and bombesin. Life Sci 72:2305\u20132320","journal-title":"Life Sci"},{"key":"2424_CR2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.tem.2004.07.002","volume":"15","author":"AV Schally","year":"2004","unstructured":"Schally AV, Nagy A (2004) Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 15:300\u2013310","journal-title":"Trends Endocrinol Metab"},{"key":"2424_CR3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1358\/dof.2002.027.04.666175","volume":"27","author":"A Nagy","year":"2002","unstructured":"Nagy A, Schally AV (2002) Cytotoxic analogs of luteinizing hormone-releasing hormone (LH-RH); a new approach to targeted chemotherapy. Drugs Future 27:359\u2013370","journal-title":"Drugs Future"},{"key":"2424_CR4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/frne.2001.0217","volume":"22","author":"AV Schally","year":"2001","unstructured":"Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A et al (2001) Hypothalamic hormones and cancer. Front Neuroendocrinol 22:248\u2013291","journal-title":"Front Neuroendocrinol"},{"key":"2424_CR5","first-page":"911","volume-title":"Cancer medicine","author":"AV Schally","year":"2003","unstructured":"Schally AV, Comaru-Schally AM (2003) Hypothalamic and other peptide hormones. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E III (eds) Cancer medicine, 6th edn. BC Decker, Ontario, pp 911\u2013926","edition":"6"},{"key":"2424_CR6","first-page":"161","volume":"30","author":"S Stojilkovic","year":"1995","unstructured":"Stojilkovic S, Catt KJ (1995) Expression and signal transduction pathways of gonadotropin releasing hormone receptors. Recent Prog Horm Res 30:161\u2013205","journal-title":"Recent Prog Horm Res"},{"key":"2424_CR7","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1158\/1078-0432.CCR-10-1113","volume":"16","author":"SV Liu","year":"2010","unstructured":"Liu SV, Schally AV, Hawes D, Xiong S, Fazli L, Gleave M et al (2010) Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res 16:4675\u20134680","journal-title":"Clin Cancer Res"},{"key":"2424_CR8","first-page":"17","volume-title":"Infertility and reproductive medicine clinics of North America: GnRH analogs","author":"AV Schally","year":"2001","unstructured":"Schally AV, Halmos G, Rekasi A (2001) The actions of LH-RH agonists, antagonists, and cytotoxic analogs on the LH-RH receptors on the pituitary and tumors. In: Devroey P (ed) Infertility and reproductive medicine clinics of North America: GnRH analogs. Saunders, Pennsylvania, pp 17\u201344"},{"key":"2424_CR9","first-page":"1481","volume":"25","author":"C F\u00f6st","year":"2011","unstructured":"F\u00f6st C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gruendker C (2011) Targeted chemotherapy for tripe-negative breast cancers via LHRH-receptor. Oncol Rep 25:1481\u20131487","journal-title":"Oncol Rep"},{"key":"2424_CR10","first-page":"489","volume":"12","author":"G Srkalovic","year":"1998","unstructured":"Srkalovic G, Schally AV, Wittliff JL, Day TG Jr, Jenison EL (1998) Presence and characteristics of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 12:489\u2013498","journal-title":"Int J Oncol"},{"key":"2424_CR11","first-page":"1063","volume":"17","author":"S Westphalen","year":"2000","unstructured":"Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP et al (2000) Receptor mediated antiproliferative effects of the cytotoxic LH-RH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 17:1063\u20131069","journal-title":"Int J Oncol"},{"key":"2424_CR12","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1073\/pnas.88.10.4153","volume":"88","author":"B Szende","year":"1991","unstructured":"Szende B, Srkalovic G, Timar J, Mulchahey JJ, Neill JD, Lapis K et al (1991) Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells. Proc Natl Acad Sci USA 88:4153\u20134156","journal-title":"Proc Natl Acad Sci USA"},{"key":"2424_CR13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.18632\/oncotarget.546","volume":"3","author":"K Szepeshazi","year":"2012","unstructured":"Szepeshazi K, Schally AV, Keller G, Block NL, Benten D, Halmos G et al (2012) Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108). Oncotarget 3:686\u2013699","journal-title":"Oncotarget"},{"key":"2424_CR14","first-page":"1485","volume":"30","author":"K Szepeshazi","year":"2007","unstructured":"Szepeshazi K, Schally AV, Halmos G (2007) LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int J Oncol 30:1485\u20131492","journal-title":"Int J Oncol"},{"key":"2424_CR15","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1158\/0008-5472.CAN-04-3816","volume":"65","author":"G Keller","year":"2005","unstructured":"Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Westphal G et al (2005) Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue. Cancer Res 65:5857\u20135863","journal-title":"Cancer Res"},{"key":"2424_CR16","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-04-2464","volume":"11","author":"G Keller","year":"2005","unstructured":"Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G et al (2005) Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clin Cancer Res 11:5549\u20135557","journal-title":"Clin Cancer Res"},{"key":"2424_CR17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1517\/13543784.2012.685128","volume":"6","author":"J Engel","year":"2012","unstructured":"Engel J, Emons G, Pinski J, Schally AV (2012) AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs 6:891\u2013899","journal-title":"Expert Opin Investig Drugs"},{"key":"2424_CR18","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.ejca.2005.06.018","volume":"41","author":"G Keller","year":"2005","unstructured":"Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G et al (2005) Receptors for luteinizing hormone releasing hormone (LH-RH) expressed in human non-Hodgkin\u2019s lymphomas can be targeted for therapy with the cytotoxic LH-RH analogue AN-207. Eur J Cancer 41:2196\u20132202","journal-title":"Eur J Cancer"},{"key":"2424_CR19","doi-asserted-by":"crossref","first-page":"12962","DOI":"10.1073\/pnas.0504274102","volume":"102","author":"SS Dharap","year":"2005","unstructured":"Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S et al (2005) Tumor specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci 102:12962\u201312967","journal-title":"Proc Natl Acad Sci"},{"key":"2424_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1016-8478(23)13504-7","volume":"9","author":"YS Gho","year":"1999","unstructured":"Gho YS, Chae CB (1999) Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LH-RH-receptor-positive human prostate and breast tumor cells. Mol Cells 9:31\u201336","journal-title":"Mol Cells"},{"key":"2424_CR21","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/0008-5472.CAN-3192-2","volume":"64","author":"L Qi","year":"2004","unstructured":"Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA et al (2004) Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptors. Cancer Res 64:2090\u20132095","journal-title":"Cancer Res"},{"key":"2424_CR22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0014-5793(00)01469-1","volume":"472","author":"J Schlick","year":"2000","unstructured":"Schlick J, Dulieu P, Desvoyes B, Adami P, Radom J, Jouvenot M (2000) Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines. FEBS Lett 472:241\u2013246","journal-title":"FEBS Lett"},{"key":"2424_CR23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1185>3.0.CO;2-E","volume":"92","author":"A Ben-Yehudah","year":"2001","unstructured":"Ben-Yehudah A, Prus D, Lorberboum-Galski H (2001) I.V. administration of L-GnRH-PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice. Int J Cancer 92:263\u2013268","journal-title":"Int J Cancer"},{"key":"2424_CR24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/14737140.4.1.151","volume":"4","author":"A Ben-Yehudah","year":"2004","unstructured":"Ben-Yehudah A, Lorberboum-Galski H (2004) Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev Anticancer Ther 4:151\u2013161","journal-title":"Expert Rev Anticancer Ther"},{"key":"2424_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/eje.0.1410001","volume":"141","author":"AV Schally","year":"1999","unstructured":"Schally AV, Nagy A (1999) Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 141:1\u201314","journal-title":"Eur J Endocrinol"},{"key":"2424_CR26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijpharm.2011.05.072","volume":"415","author":"M P\u0159ibylov\u00e1","year":"2011","unstructured":"P\u0159ibylov\u00e1 M, Dvo\u0159\u00e1kov\u00e1 M, Hanu\u0161ov\u00e1 V, Nemetova J, Skalova L, Vanek T (2011) Paclitaxel conjugation with the analog of the gonadotropin-releasing hormone as a targeting moiety. Int J Pharm 415:175\u2013180","journal-title":"Int J Pharm"},{"key":"2424_CR27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0005-2736(99)00205-9","volume":"1462","author":"B Bechinger","year":"1999","unstructured":"Bechinger B (1999) The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy. Biochim Biophys Acta 1462:157\u2013183","journal-title":"Biochim Biophys Acta"},{"key":"2424_CR28","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2174\/1381612043383971","volume":"10","author":"C Leuschner","year":"2004","unstructured":"Leuschner C, Hansel W (2004) Membrane disrupting lytic peptides for cancer treatments. Curr Pharm Des 10:2299\u20132310","journal-title":"Curr Pharm Des"},{"key":"2424_CR29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389\u2013395","journal-title":"Nature"},{"key":"2424_CR30","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1158\/0008-5472.CAN-09-3267","volume":"70","author":"SM Standley","year":"2010","unstructured":"Standley SM, Toft DJ, Cheng H, Soukasene S, Chen J et al (2010) Induction of cancer cell death by self assembling nanostructures incorporating a cytotoxic peptide. Cancer Res 70:3020\u20133026","journal-title":"Cancer Res"},{"issue":"10","key":"2424_CR31","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1158\/0008-5472.CAN-05-4569","volume":"66","author":"N Papo","year":"2006","unstructured":"Papo N, Seger D, Makovitzki A, Vyachaeslav K, Eshhar Z, Degani H et al (2006) Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense\u2013like lytic peptide. Cancer Res 66(10):5371\u20135378","journal-title":"Cancer Res"},{"key":"2424_CR32","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1046\/j.1432-1327.2001.02039.x","volume":"268","author":"HM Chen","year":"2001","unstructured":"Chen HM, Clayton AHA, Wang W, Sawyer WH (2001) Kinetics of membrane lysis by custom lytic peptides and peptide orientations in membrane. Eur J Biochem 268:1659\u20131669","journal-title":"Eur J Biochem"},{"key":"2424_CR33","first-page":"7709","volume":"61","author":"JC Mai","year":"2001","unstructured":"Mai JC, Mi Z, Kim SH, Ng B, Robbins PD (2001) A proapoptotic peptide for the treatment of solid tumors. Cancer Res 61:7709\u20137712","journal-title":"Cancer Res"},{"key":"2424_CR34","first-page":"3062","volume":"51","author":"T Utsugi","year":"1991","unstructured":"Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ (1991) Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51:3062\u20133066","journal-title":"Cancer Res"},{"key":"2424_CR35","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.peptides.2008.12.019","volume":"30","author":"T Iwasaki","year":"2009","unstructured":"Iwasaki T, Ishibashi T, Tanaka H, Sato M, Asaoka A, Taylor T et al (2009) Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface. Peptides 30:660\u2013668","journal-title":"Peptides"},{"key":"2424_CR36","unstructured":"Leuschner C, Keener J, McCabe R, Patel N, Alila HW (2009) Targeted oncolytic peptide for treatment of ovarian cancers (abstract). In: Proceedings of the 100th annual meeting of the American Association for Cancer Research, 2009 April 18\u201322, Denver, CO. AACR, Philadelphia (PA). Abstract nr 4666"},{"key":"2424_CR37","unstructured":"Leuschner C, Coulter A, Giardina C, Alila HW (2012) Activity of EP-100 in non-Hodgkin\u2019s lymphoma\u2014synergy in combination (abstract). In: Proceedings of the 103rd annual meeting of the American Association for Cancer Research, 2012 March 31\u2013April 4, Chicago, IL. AACR, Philadelphia (PA). Abstract nr 2829"},{"key":"2424_CR38","unstructured":"Guidance for Industry (2005) Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Food and Drug Administration, Rockville. Available from: http:\/\/www.fda.gov\/cder\/guidance\/index.htm"},{"key":"2424_CR39","unstructured":"Leuschner C, Giardina C, Alila HW (2012) EP-100 synergizes with paclitaxel in ovarian, breast and prostate cancer cell lines (abstract). In: Proceedings of the 103rd annual meeting of the American Association for Cancer Research, 2012 March 31\u2013April 4, Chicago, IL. AACR, Philadelphia (PA). Abstract nr 3715"},{"key":"2424_CR40","doi-asserted-by":"crossref","unstructured":"Leuschner C, Gavini S, Alila HW (2013) Synergistic activity of EP-100 and chemotherapies in cancer cell lines (abstract). In: Proceedings of the 104th annual meeting of the American Association for Cancer Research, 2013 April 6\u201310, Washington, DC. AACR, Philadelphia (PA). Abstract nr 978","DOI":"10.1158\/1538-7445.AM2013-978"},{"key":"2424_CR41","unstructured":"Esperance Pharmaceuticals, Inc. (2011) EP-100 plus paclitaxel versus paclitaxel alone in patients with ovarian cancer (ESP2011-002). In: clinicaltrials.gov (Internet). National Library of Medicine (US), Bethesda (MD). (cited 2012 Sept 5). Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01485848 . NLM Identifier: NCT01485848"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2424-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2424-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T17:41:16Z","timestamp":1716572476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2424-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,8]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2424"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2424-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,8]]}}}